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Introduction
Fabry’s disease (FD) is one of those rare disorders which are 
highly undiagnosed. The reported incidence of this disorder 
is 1/40,000 males.[1] FD being a rare cause of end-stage 
renal disease (ESRD), accounts for 0.0167% of all causes of 
ESRD.[2] Manifestations of FD are often more severe in men 
due to the very low residual function of alpha-galactosidase. 
Heterozygous females may be asymptomatic except for corneal 
opacities or depending on lyonization or random X-inactivation, 
they may be as severely affected as homozygous males.[3]
We hereby report five patients with FD having ESRD. One 
of the patients received a human leukocyte antigen-identical 
transplant from his brother whose pretransplant workup 
was negative but was not tested for FD. Posttransplant, 
the recipient, developed progressive worsening of serum 
creatinine and proteinuria and was biopsied. The biopsy 
showed features suggestive of acute T-cell mediated rejection 
in allograft with diffuse vacuolization of visceral epithelial 
cells causing suspicion of a metabolic disease (e.g., FD). 
Subsequent enzymatic and pedigree analysis confirmed the 
diagnosis of FD in the recipient and one of his brothers with the 
possibility of their mother being an affected carrier. Four years 
posttransplant, the patient continues to have progressively 
worsening serum creatinine. The other four patients were 
diagnosed on the basis of clinical suspicion and confirmed by 
low enzymatic levels of alpha-galactosidase A. The pedigree 
analysis revealed that the male members of the family had low 
enzyme levels and are being planned for treatment with enzyme 
replacement therapy (ERT). Three patients are described below.
Case Reports
Case 1
The patient is a 45-year-old male who presented in 2009 with 
proteinuria, high serum creatinine and bilateral shrunken 
kidneys on ultrasonography (USG) and was diagnosed as ESRD. 
Etiology was presumed to be chronic glomerulonephritis – exact 
etiology was not known. The patient was put on continuous 
ambulatory peritoneal dialysis protocol before transplant and 
received a living-related kidney transplant from his brother in 
2009 with excellent immediate graft function.
The patient’s immunosuppression regimen comprised pulse 
steroid therapy followed by triple immunosuppression 
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regime (prednisone, tacrolimus, and mycophenolate mofetil). 
No induction with anti-thymocyte globulin/monoclonal 
antibodies was given. During his 1st year posttransplant, he 
developed polycythemia which was managed with phlebotomy. 
After 1½ year, his serum creatinine reached 2.0 mg/dl. He was 
noted to have significant proteinuria of 4 g/day. His general 
physical and systemic examination was normal. The patient 
underwent a renal transplant biopsy to ascertain the cause of 
worsening creatinine and proteinuria.
The biopsy contained renal medulla and cortical parenchyma 
containing up to 7 viable glomeruli [Figure 1]. One glomerulus 
showed global sclerosis. Remaining glomeruli appeared 
variably enlarged and exhibited dilated capillary lumina. 
Two glomeruli showed segmental sclerosis with a monolayer 
of visceral epithelial cells overlying the sclerosed segments. 
There was remarkable global enlargement of visceral epithelial 
cells which contained abundant vacuolated cytoplasm, with 
few cells containing cytoplasmic basophilic debris. Tubular 
atrophy and interstitial fibrosis involved about 15–20% of 
sampled cortex. Patchy dense interstitial inflammation and 
mild interstitial edema with a few foci of moderate tubulitis 
affecting the nonatrophic tubules were noted. Patchy loss 
of tubular brush borders with epithelial simplification and 
luminal granular casts were seen. Few atrophic tubules were 
dilated and contained luminal hyaline/proteinaceous casts 
whereas few tubular lumina contained red blood cells (RBC’s). 
Arteries appeared relatively unremarkable while arterioles 
showed focally marked hyalinosis. Focal RBC extravasation 
and interstitial inflammation were noted in the medullary 
parenchyma. Tissue for immunofluorescence showed up to 5 
glomeruli, exhibiting segmental mesangial staining for IgM, 
and were negative for IgA, IgG, C3 and C1q.
The patient received pulse doses of methylprednisolone 
for cell-mediated rejection and was continued on 
immunosuppressive regime of prednisone, tacrolimus and 
mycophenolate mofetil, and olmesartan for proteinuria. 
Serum creatinine initially improved to 1.7 mg/dl. However, 
subsequent testing revealed worsening serum creatinine to 
2.7 mg/dl. In view of renal biopsy showing visceral epithelial 
cells containing abundant vacuolated cytoplasm, patient 
was evaluated for alpha-galactosidase A enzyme activity. 
Levels of the enzyme was found markedly deficient in the 
recipient (7.00; enzyme normal limit >60). Diagnosis of FD 
was confirmed in the recipient. Further evaluation revealed 
normal electrocardiogram and normal echocardiography. There 
was mild acroparesthesias in the hands and feet of the recipient. 
The renal function of the donor continued to remain within 
normal limits (serum creatinine 0.8 mg/dl and urinary protein 
of <50 mg/24 h). The alpha-galactosidase level of donor was 
normal on evaluation.
A pedigree analysis showed recipient was second in birth 
order and had four more brothers. A second sibling, another 
brother, fourth in birth order, who was evaluated for infertility 
was found to have raised serum creatinine (serum creatinine 
of 4 mg/dl) with proteinuria of 5.8 g/24 h. He was evaluated 
for alpha-galactosidase activity which was found markedly 
decreased (12.10; normal enzyme activity level >60), and was 
diagnosed as FD with renal failure. The mother of the patient 
had died at around 55 years of age due to chronic kidney 
disease (CKD)/ESRD, the etiology of which was not known 
as she was not evaluated for it. The father is alive at the age 
of 90 years and is well. Three other brothers are not affected. 
His mother has three more siblings who are all alive and well 
with ages more than 75, but have not been evaluated for FD. 
The children of the patient are being evaluated for FD.
The patient is being planned for ERT. However, due to financial 
constraints has still not been started on ERT.
Case 2
A 16-year-old male presented in March 2002 with a fever 
of unknown origin and splenomegaly. The investigations 
revealed normal renal functions. USG of the abdomen 
revealed splenomegaly and echocardiography was normal. 
He was treated with antibiotics. The patient again presented 
in June, 2009 (now age 25 years) with fever, headache, loss 
of vision, and chest pain. Ophthalmological consultation 
revealed cloudy cornea and features of anterior ischemic optic 
neuropathy and patient was advised three doses of injectable 
methylprednisoslone. Magnetic resonance imaging of the brain 
done revealed nonspecific white matter hyperintensities in the 
left high parietal lobe. Echocardiography revealed severe left 
ventricular hypertrophy likely of the variant, hypertrophic 
cardiomyopathy. Urine examination revealed Alb ++ and 
24 h urinary protein estimated 1 g/day. Serum creatinine 
was 2.7 mg/dl. The USG revealed bilateral small kidneys 
with borderline hepatosplenomegaly. In view of multisystem 
involvement, serum alpha-galactosidase level was done which 
Figure 1: Photomicrograph depicting mesangial matrix expansion, 
foamy cytoplasm with vacuolation in visceral epithelial cells. Few 
glomeruli appear variably enlarged and exhibited dilated capillary 
lumina
Wani, et al.: Fabry’s disease
Annals of Medical and Health Sciences Research | May-Jun 2016 | Vol 6 | Issue 3 | 195
estimated 25 nmol/h/mg (normal >60 nmol/h/mg). There were 
mild acroparesthesias in the hands and feet. In March 2013, he 
was readmitted whereby his renal functions revealed creatinine 
of 9.36 mg/dl and USG revealed small-sized kidneys. Recently, 
patient was admitted with seizures and advanced renal failure. 
Patient has been planned for renal replacement therapy (RRT). 
The pedigree analysis revealed that he had three brothers 
with complaints of decreased vision. They are planned for 
alpha-galactosidase A levels and appropriate ERT.
Case 3
A 30-year-old female, historically normotensive, nondiabetic 
presented to us with 2 years history of pedal edema and 
periorbital swelling. On evaluation in 2011, her urine 
examination revealed Alb - 3+, pus cells - 18–20. Twenty-four 
hours urinary protein had been 1.8 g/day. Kidney function 
tests revealed creatinine of 1.3 mg/dl. The right kidney was 
8.8 × 2.9 in size and left kidney was 7.8 cm × 3.3 cm in size 
with normal hepatobillary and pelvic system. Her anti-nuclear 
antibody titer (an ANA was 5.84 IU/ml, positive >1.2 IU/ml). 
The patient had been reluctant for renal biopsy. She had been 
treated with oral steroids and angiotensin receptor blocking 
agents. She presented to our department on November 2013. 
A full evaluation was sought. Her urine examination revealed 
Alb 2+, RBC 1–2, pus cells 4–5. Twenty-four hours urinary 
protein estimation was 1.38 g/day. Serum creatinine was 
1.85 mg/dl. ANA, anti-dsDNA had been negative. Patient was 
subjected to renal biopsy. The examination of the renal tissue 
revealed up to seven glomeruli, one was globally sclerosed. 
Rest of the glomeruli displayed variably enlarged capillary tufts 
with patchy, segmental, and mild mesangial matrix expansion. 
Extracapillary cells (chiefly podocytes) were enlarged and 
displayed a foamy/finely vacuolated cytoplasm. No mesangial 
or endocapillary proliferation was noted and the peripheral 
glomerular capillary loops did not show significant thickening. 
There was no evidence of tuft necrosis/crescent formation or 
segmental sclerosis in the sampled glomeruli [Figure 2].
Foci of tubular atrophy and interstitial fibrosis were seen 
involving approximately 15–20% of the sampled cortical 
parenchyma. The atrophic tubules contained inspissated 
hyaline casts. An associated, mild to moderate chronic 
interstitial inflammatory infiltrate was seen. The nonatrophic 
tubules showed patchy loss of brush borders with epithelial 
attenuation. The arteries sampled showed medial thickening 
and mild fibrointimal hyperplasia with elastic reduplication.
On differential immunofluorescence (DIF), sections included 
up to nine glomeruli exhibiting the following immunostaining 
features-IgA negative, IgG - 3+, IgM - Trace, C3 - negative, 
C1q - 3+/4+, kappa light chains - 1+/2+, lambda light 
chains - 2+. The entire staining pattern above was predominantly 
mesangial. The glomeruli exhibited nonproliferative 
morphology with variably enlarged capillary tufts exhibiting 
patchy, segmental, mild mesangial matrix expansion, and 
prominent enlarged extracapillary cells (chiefly podocytes) 
which display a foamy/finely vacuolated cytoplasm.
Further special stains were performed on this biopsy. Periodic 
acid–schiff (PAS) stained, frozen-sections of saline preserved 
tissue revealed intracytoplasmic PAS-positive granules within 
the podocytes/parietal epithelial cells. On examination of 
unstained frozen-sections under polarized light, these granules 
showed a Maltese cross pattern. With these DIF findings 
of non specific mesangial entrapment of complement and 
immunoglobulin, a possibility of renal involvement in a 
metabolic disorder viz., FD was suggested.
The pedigree analysis revealed that the patient had three 
brothers and one sister. Clinical examination showed 
angiokeratoma and corneal haziness in father and one of the 
brothers. Enzyme levels in all members had been sent.
The clinical characteristics of the studied population is shown 
in table 1.
Discussion
FD is a rare lysosomal storage disease leading to progressive 
globotriaosylceramide (GL-3) accumulation in multiple cell 
types and tissues with end organ damage. More than 500 
different mutations have been identified in long arm of the X 
chromosome.
Renal dysfunction and ultimately ESRD occurs in classically 
affected males and in about 10–15% of female heterozygotes. 
FD is a rare cause of ESRD, accounting for 0.0167% of all 
causes of ESRD (according to US Renal Data System [USRDS] 
analysis),[2,4,5] 0.0188% (according to European Renal 
Association-European Dialysis and Transplant Association).[6] 
Patients with FD are younger and more likely to be male and 
white. Mean age was 42 years and the majority of patients 
began RRT between the ages of 35 and 44 years in USRDS.[5]
Our case series is important because of following reasons: 
(1) FD is under-diagnosed and screening of high-risk groups 
Figure 2: Histopathological examination exhibiting (a) nonproliferative 
glomerular morphology (variably enlarged capillary tufts with patchy, 
segmental, mild mesangial matrix expansion, and prominent enlarged 
visceral epithelial cells which display a foamy/finely vacuolated 
cytoplasm) and (b) intense, granular, mesangial C1q deposits, and 
co‑dominant immunostaining for IgG (without evidence of light chain 
restriction)
a b
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is important for case finding and our observation highlights 
the same need (2) this case series highlights the importance of 
screening those patients for CKD who have unexplained renal 
failure (3) it highlights the need for pretransplant evaluation 
for FD.
Proteinuria is often the first sign of kidney involvement. 
Patient may present with proteinuria, isosthenuria and gradual 
deterioration of renal function. Development of azotaemia 
occurs in second through fourth decades.[1] In all the five 
patients, the diagnosis of FD was established after the diagnosis 
of renal disease. The diagnosis was established by enzyme 
level estimation and renal biopsy. In two patients, angiotensin 
receptor blockers (ARBs) were used for proteinuria to which 
patient responded well to. Recently, Tahir et al. found reduction 
in proteinuria after use of ARBs.[7]
Fabry nephropathy is one of the most severe manifestations of 
FD. It had been one of the unknown causes of morbidity and 
mortality before the widespread availability of dialysis and 
kidney transplantation. Like most aspects of FD, kidney disease 
is thought to result from GL-3 accumulation in glomerular 
endothelial, mesangial and interstitial cells, podocytes, and 
renal vasculature. Progressive intracellular accumulation of 
GL-3 is thought to cause glomerulosclerosis and interstitial 
fibrosis[8] as well as its urinary excretion together with other 
lipids.[9]
The clinical manifestations of FD in females tend to be less 
severe and present later than in males.[10] In this regard, they 
may develop albuminuria and progressive renal dysfunction 
leading to the need of RRT.[11,12]
Diagnosis may be presumptive based on observation of 
symptoms and laboratory findings with family history and 
medical pedigree. Definitive diagnosis is made by enzyme 
assay and gene mutation analysis or linkage analysis. 
Prenatal detection of affected males may be accomplished 
by demonstration of deficient α galactosidase A activity 
or the family’s specific gene mutation in chorionic villi 
obtained in the first trimester or in cultured amniocytes 
obtained by amniocentesis in the second trimester of 
pregnancy.[1]
Treatment includes ERT and RRT in the form of dialysis or 
kidney transplantation. The use of ARBs has been shown to 
be nephro-protective in other proteinuric renal diseases, and 
could thus be important in FD as well.[13]
Kidney Disease Improving Global Outcomes guidelines 
suggest that in patients with CKD Stages 3–5, Vitamin D 
deficiency be corrected. Vitamin D can reduce proteinuria or 
albuminuria.[14]
Newer modalities under research include gene therapy 
substrate deprivation. Studies on ERT of FD patients on 
dialysis are warranted, as this may be the only hope as these 
patients have to improve survival on dialysis.
Although kidney transplantation is considered the optimal 
therapy for ESRD in suitable patients, it is not universally 
accepted as the ideal treatment for patients who have 
suffered ESRD from FD. Recent estimates of rate of 
transplantation of Fabry patients compared with matched 
controls appear to be similar, suggesting this practice may 
be changing.[2,5,6] Successful kidney transplantation in FD 
has been reported by several kidney transplant programs in 
the United States and Western Europe,[5,15,16] although there 
are case reports of recurrence of FD in the transplanted 
kidney.[17-20] FD patients that initiate dialysis have a worse 
survival compared with non-FD controls, even when one 
accounts for age.
Table 1: Clinical characteristics of the studied population
Patient characteristics 1 2 3 4 5
Age 45 16 30 24 38
Sex Male Male Female Female Male






Parsthesia, edema legs, 
weakness lower limbs
CKD‑IV with chest pain, 
pain abdomen, vomiting
Creatininine (mg/dl) 2/1.7/2.7 2.7/9.3 1.3 3.0 2.8
Proteinuria (g/day) 4 1 1.8 2 2.5
Alpha‑galactosidase 
(nmol/h/mg)
7 25 20 ND 18
Renal biopsy Conclusive Conclusive Conclusive Conclusive Conclusive
Etiology FD FD FD FD FD
Family history Positive for FD Positive for FD Not proven, 
under evaluation
Positive Not evaluated
Other findings Nil Splenomegaly Nil Septal hypertrophy Hepatosplenomegaly
ERT Not given Given Given Given No
RRT Yes Yes Not applicable Not applicable Planned
Outcome Under observation Improved Improved Under observation Under observation
ND: Not done, FD: Fabry’s disease, ERT: Enzyme replacement therapy, RRT: Renal replacement therapy, ESRD: End‑stage renal disease, CKD: Chronic kidney disease
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Conclusion
Evaluation for FD is still not included in the regular protocols 
followed all over the world in pretransplant work-up of donor 
or recipient. There is clearly a need to evaluate whether all 
kidney transplant recipients and living donors should undergo 
testing for FD prior to transplantation.
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